hotspot -WSS

hotspot

author：entertainment 2025-09-28 18:30:53 - browse：77325

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： What affirmative action's end means to a medical student

entertainment

WSS

Dexcom's push to bring CGM to type 2 diabetes patients

Flagship Pioneering launches a new biotech in two countries

UnitedHealth’s Optum accused of antitrust violations in California

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Drug cartel violence flares in western Mexico after vigilante leader's killing

Will the market for weight loss drugs really reach $100 billion?

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Supreme Court strikes down use of affirmative action

Lupron, used to halt puberty in children, may cause lasting health problems

Apple is now the first public company to be valued at $3 trillion

Canadians with cystic fibrosis outlive Americans by a decade

23andMe had bad news about my health. I wish a person had delivered it

Will the market for weight loss drugs really reach $100 billion?

Peter Hotez and the public health issue of online harassment

Despite FDA concern, risk that CAR

How one medical school became remarkably diverse

J&J to emphasize cancer drugs, stop much of its vaccine research

focus

STAT wants to know your pick for a great summer read or listen

Beware reading your test results before your doctor does

CDC director unscathed in first congressional testimony

Security flaws in third

A letter from the executive editor: The 2023 STATUS List

'Screen and refer' systems are hurting patients

Wikipedia

knowledge

entertainment

focus